None of the three studies involving DPP4 inhibitors showed an increased risk of cardiovascular events (death due to cardiovascular causes, nonfatal infarcts, nonfatal strokes, hospitalization for unstable angina) in a wide spectrum of patients with DMT2 (primary prevention with high-risk patients, secondary prevention, recent acute coronary syndrome) 45-47. Here, DPP4 is linked to angina pectoris.